Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year High at $22.05

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares reached a new 52-week high on Tuesday . The stock traded as high as $22.05 and last traded at $21.83, with a volume of 42592 shares traded. The stock had previously closed at $20.78.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TYRA shares. Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd.

Tyra Biosciences Stock Up 5.0 %

The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -13.01 and a beta of 1.01. The stock’s 50-day moving average price is $18.07 and its 200-day moving average price is $17.10.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. On average, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.71 EPS for the current year.

Insider Activity

In related news, COO Daniel Bensen sold 3,502 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $20.00, for a total value of $70,040.00. Following the transaction, the chief operating officer now owns 427,981 shares in the company, valued at $8,559,620. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its holdings in Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after acquiring an additional 3,180,155 shares during the last quarter. BVF Inc. IL lifted its stake in Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares during the period. Vanguard Group Inc. lifted its stake in Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after buying an additional 140,833 shares during the period. Kynam Capital Management LP lifted its stake in Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock valued at $8,449,000 after buying an additional 175,000 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Tyra Biosciences by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the period. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.